JP2020534355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534355A5 JP2020534355A5 JP2020537064A JP2020537064A JP2020534355A5 JP 2020534355 A5 JP2020534355 A5 JP 2020534355A5 JP 2020537064 A JP2020537064 A JP 2020537064A JP 2020537064 A JP2020537064 A JP 2020537064A JP 2020534355 A5 JP2020534355 A5 JP 2020534355A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- alkyl
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 102100040460 P2X purinoceptor 3 Human genes 0.000 claims 6
- 101710189970 P2X purinoceptor 3 Proteins 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 102100040479 P2X purinoceptor 2 Human genes 0.000 claims 2
- 101710189968 P2X purinoceptor 2 Proteins 0.000 claims 2
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 230000008485 antagonism Effects 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000013116 chronic cough Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000036327 taste response Effects 0.000 claims 1
- SEHLMRJSQFAPCJ-HNNXBMFYSA-N Cc1cc2nc(-c(c(F)cc(C(NC)=O)c3)c3F)c(C[C@@H](C3)OCCN3C(OC)=O)[n]2cc1 Chemical compound Cc1cc2nc(-c(c(F)cc(C(NC)=O)c3)c3F)c(C[C@@H](C3)OCCN3C(OC)=O)[n]2cc1 SEHLMRJSQFAPCJ-HNNXBMFYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560077P | 2017-09-18 | 2017-09-18 | |
| US62/560,077 | 2017-09-18 | ||
| US15/936,316 US10111883B1 (en) | 2017-09-18 | 2018-03-26 | Selective P2X3 modulators |
| US15/936,316 | 2018-03-26 | ||
| PCT/IB2018/001513 WO2019064079A2 (en) | 2017-09-18 | 2018-09-14 | SELECTIVE MODULATORS OF P2X3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534355A JP2020534355A (ja) | 2020-11-26 |
| JP2020534355A5 true JP2020534355A5 (cg-RX-API-DMAC7.html) | 2021-10-21 |
| JP7242681B2 JP7242681B2 (ja) | 2023-03-20 |
Family
ID=63894683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537064A Active JP7242681B2 (ja) | 2017-09-18 | 2018-09-14 | 選択的ｐ２ｘ３修飾薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US10111883B1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4331669A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7242681B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102713354B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111601601A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018342751B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3076150C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2969868T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL303257A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020002968A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202002460QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019064079A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3862000T3 (pl) * | 2018-10-05 | 2024-03-18 | Shionogi & Co., Ltd | Lek na przewlekły kaszel |
| KR20210074315A (ko) * | 2018-10-10 | 2021-06-21 | 벨루스 헬스 코프 인크. | P2x3 길항제를 사용한 소양증의 치료 |
| LT3880678T (lt) | 2018-11-13 | 2025-06-25 | Glaxosmithkline Intellectual Property (No.3) Limited | P2x3 moduliatoriaus metilo (s)-2-((2-(2,6-difluor-4-(metilkarbamoil)fenil) -7-metilimidazo[1,2-a]piridin-3-il)metil)morfolin-4-karboksilato kristalinės formos |
| SG11202106706TA (en) * | 2018-12-29 | 2021-07-29 | Wuhan Ll Science And Technology Development Co Ltd | Heterocyclic compound intermediate, preparation method therefor and application thereof |
| AU2020228760A1 (en) | 2019-02-25 | 2021-09-23 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment with P2X3 modulators |
| CN112409331B (zh) * | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| MX2022009762A (es) * | 2020-02-14 | 2022-09-09 | Bellus Health Cough Inc | Moduladores del purinorreceptor 3 p2x (p2x3). |
| BR112022021789A2 (pt) | 2020-04-27 | 2023-03-07 | Twist Bioscience Corp | Bibliotecas de ácido nucléico variantes para coronavírus |
| CN113754654A (zh) * | 2020-06-05 | 2021-12-07 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| CN114085220B (zh) * | 2020-06-22 | 2023-06-16 | 上海海雁医药科技有限公司 | 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途 |
| CA3184482A1 (en) * | 2020-06-29 | 2022-01-06 | Liang Wang | Crystalline form of heterocyclic compound, preparation method therefor and application thereof |
| US20230218661A1 (en) * | 2022-01-10 | 2023-07-13 | Sensory Cloud, Inc. | Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx |
| US20240408131A1 (en) * | 2020-07-06 | 2024-12-12 | Sensory Cloud, Inc. | Isotonic or hypertonic salt-based compositions |
| CN113912601B (zh) * | 2020-07-10 | 2023-06-06 | 上海拓界生物医药科技有限公司 | 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途 |
| WO2022033567A1 (zh) * | 2020-08-13 | 2022-02-17 | 上海拓界生物医药科技有限公司 | 苯并咪唑类衍生物、其制备方法及医药用途 |
| CN116635389A (zh) * | 2021-01-29 | 2023-08-22 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| CN115463133B (zh) * | 2021-06-10 | 2024-03-01 | 武汉朗来科技发展有限公司 | 一种药物组合物、制剂及其制备方法和应用 |
| WO2023020156A1 (zh) * | 2021-08-20 | 2023-02-23 | 苏州璞正医药有限公司 | 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途 |
| WO2024194352A1 (en) | 2023-03-23 | 2024-09-26 | Glaxosmithkline Intellectual Property (No.3) Limited | Deuterated p2x3 modulators |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102741245B (zh) * | 2009-11-18 | 2014-11-05 | 尼奥梅德研究院 | 苯并咪唑化合物及其用途 |
| US20130053338A1 (en) * | 2010-03-19 | 2013-02-28 | Per-Olof Berggren | Use of P2X Purinergic Receptor Agonists to Enhance Insulin Secretion in Pancreatic Beta Cells |
| EP2951177B1 (en) * | 2013-01-31 | 2018-04-04 | Neomed Institute | Imidazopyridine compounds and uses thereof |
| NZ716977A (en) * | 2013-08-23 | 2017-09-29 | Afferent Pharmaceuticals Inc | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases |
| SI3587417T1 (sl) * | 2014-12-09 | 2022-04-29 | Bayer Ag | 1,3-tiazol-2-il substituirani benzamidi |
| EP3355889B1 (en) * | 2015-09-29 | 2023-02-15 | Afferent Pharmaceuticals Inc. | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| EP3528813B1 (en) * | 2016-09-30 | 2025-04-16 | ABS Development 1, Inc. | P2x3 and/or p2x2/3 compounds and methods |
-
2018
- 2018-03-26 US US15/936,316 patent/US10111883B1/en active Active
- 2018-09-14 JP JP2020537064A patent/JP7242681B2/ja active Active
- 2018-09-14 EP EP23219770.7A patent/EP4331669A3/en active Pending
- 2018-09-14 KR KR1020207010982A patent/KR102713354B1/ko active Active
- 2018-09-14 CA CA3076150A patent/CA3076150C/en active Active
- 2018-09-14 ES ES18860273T patent/ES2969868T3/es active Active
- 2018-09-14 SG SG11202002460QA patent/SG11202002460QA/en unknown
- 2018-09-14 MX MX2020002968A patent/MX2020002968A/es unknown
- 2018-09-14 US US16/647,821 patent/US20200230148A1/en not_active Abandoned
- 2018-09-14 IL IL303257A patent/IL303257A/en unknown
- 2018-09-14 WO PCT/IB2018/001513 patent/WO2019064079A2/en not_active Ceased
- 2018-09-14 IL IL273348A patent/IL273348B2/en unknown
- 2018-09-14 CN CN201880073147.XA patent/CN111601601A/zh active Pending
- 2018-09-14 EP EP18860273.4A patent/EP3684368B8/en active Active
- 2018-09-14 AU AU2018342751A patent/AU2018342751B2/en active Active
-
2020
- 2020-11-17 US US16/950,742 patent/US20210069201A1/en not_active Abandoned
-
2021
- 2021-06-29 US US17/362,063 patent/US20210322432A1/en not_active Abandoned
-
2022
- 2022-02-11 US US17/669,806 patent/US20220160724A1/en not_active Abandoned
- 2022-09-14 US US17/932,200 patent/US20230248736A1/en active Pending